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Abstract
Iodide is an irreplaceable component of thyroid
hormones; therefore, a key requirement for thyroid
hormone synthesis is that iodide is actively accumulated
in the thyroid. The ability of thyroid follicular cell to
concentrate iodide relies on the functional expression of
the sodium/iodide symporter (NIS) at the plasma
membrane. Underscoring the significance of NIS for
thyroid physiology, naturally occurring loss-of-function NIS
mutations cause iodide transport defect (ITD) autosomal-
recessive disorders in which iodide accumulation is
severely or totally impaired, leading to dyshormonogenic
congenital hypothyroidism.
Up to date, sixteen different loss-of-function mutations in
the gene encoding NIS have been reported. Surprisingly,
marked clinical heterogeneity between patients harboring
the different (or even the same) NIS mutation without a
clear genotype–phenotype correlation has been
observed. Residual mutant NIS activity and iodide intake
levels have been proposed to explain the difference in the
age of onset on hypothyroidism and the development of
goiter. Significantly, genetic screening is highly
recommended in patients with severely reduced
radioiodide accumulation even in the absence of goiter.
The identification of mutations in NIS may allow
subsequent preclinical diagnoses of younger members of
the family as patients with delayed onset on
hypothyroidism had already signs of developmental delay
at time of diagnosis. Moreover, iodide supplementation
can improve thyroid function in patients with residual NIS
activity and should be considered.This review summarizes
the current knowledge regarding the molecular basis of
ITD, as well as the clinical and biochemical presentation of
patients with ITD. Moreover, we explore the latest
advances in the molecular characterization of ITD-causing
slc5a5 mutants whose study has yielded invaluable
information into the molecular mechanism of NIS and the
perspectives of understanding naturally occurring NIS
mutants to improve radioiodide therapy in thyroid cancer
as well as NIS-based gene therapy.
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The Significance of Dietary Iodide
Iodide accumulation in the thyroid gland constitutes the
first step for thyroid hormones synthesis, the only iodine-
containing hormones in vertebrates. Thyroid hormones are
essential for normal growth and development of a variety of
organ systems, especially the central nervous system [1]. As
iodine is an irreplaceable constituent of the thyroid hormones,
normal thyroid physiology relies on adequate dietary iodide
intake, gastro-intestinal iodide absorption, and proper iodide
accumulation in the thyroid follicular cell.
Iodine is extremely scarce in the environment and is
supplied to the body exclusively through the diet. Dietary
iodide deficiency during childhood may cause mild to severe
hypothyroidism and subsequently goiter, stunted growth,
retarded psychomotor development, cognitive impairment,
and even irreversible mental retardation due to thyroid
hormone deficiency [2]. Significantly, iodide deficiency
disorders are the most common preventable cause of mental
retardation in the world. Although iodine deficiency
prevention programs by iodination of table salt have virtually
eliminated iodide deficiency in several countries, nearly 2
billion individuals have insufficient iodine intake and remain on
risk to develop iodide deficiency disorders [3].
Congenital Hypothyroidism
Congenital hypothyroidism, defined as thyroid hormone
deficiency present at birth, is the most common inborn
endocrine disorder with an incidence estimated in
1:3,000-4,000 newborns. In countries with sufficient iodide
nutrition status, 80-85% of congenital hypothyroidism is
caused by genetic abnormalities resulting in thyroid dysgenesis
—agenesis, hypoplasia, ectopy, whereas 10-15% are the
consequence of a genetic defect impairing one of the steps
involved in thyroid hormone synthesis, also called
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dyshormonogenesis [4]. Other less common causes are central
hypothyroidism—absence of thyroid gland stimulation due to
a deficiency of thyroid stimulating hormone (TSH)—or defects
in peripheral thyroid hormone action, cell transport, and
metabolism [5,6].
Congenital hypothyroidism causes stunted growth and
irreversible mental retardation without early and adequate
replacement therapy. Therefore, current newborn screening
programs primarily seek to detect elevated TSH levels at birth
in response to deficient thyroid hormone production or action
that enable an early onset of levothyroxine therapy. Although
most patients with congenital hypothyroidism develop
successfully after levothyroxine replacement, patients with
defects in the metabolism of thyroid hormones cannot be
treated with levothyroxine alone [7]. Nowadays, the design of
new treatment options for patients with these rare conditions
is one of the most challenging tasks in the field of congenital
thyroid diseases.
Iodide Transport Defect (ITD)
ITD is an uncommon autosomal-recessive disorder
characterized by the inability of the thyroid follicular cell to
actively accumulate iodide, thus leading to dyshormonogenic
congenital hypothyroidism due to the scarcity of iodide [8].
The biochemical presentation of ITD is characterized, when
untreated, by hypothyroidism and enlargement of the thyroid
gland of different degree, normal to increased serum
thyroglobulin levels, severely reduced to absent radioiodide
accumulation in the thyroid and salivary glands, low iodide
saliva-to-plasma ratio (normal value>10), and high iodide
cerebrospinal fluid-to-plasma ratio (normal value
approximately 0.04) [9]. Significantly, the clinical presentation
of the resulting phenotypes varies from euthyroid to severe
hypothyroidism [8].
In patients with ITD, thyroid scintigraphy reveals severely
reduced to absent radioiodide accumulation in a normally
located thyroid gland. A normal thyroid gland accumulates
about 10-40% of ingested radioiodide, while in patients with
ITD it accumulates 0–5% and thyroid scintigraphy may suggest
thyroid dysgenesis especially when the presence of the thyroid
gland is missed by ultrasound analysis.
Since the absence of radioiodide accumulation is
generalized, deficient radioiodide accumulation is also
observed in salivary glands and stomach when whole body
scans are performed. Thyroid ultrasound examination and
serum thyroglobulin levels further helps to distinguish ITD
from other conditions with reduced iodide uptake as they
show, characteristically, a normally located thyroid gland and
normal to high thyroglobulin levels, excluding thyroid gland
dysgenesis or TSH receptor signaling defects.
The introduction of radioactive iodide isotopes into the
study of thyroid physiology [10] has been a cornerstone in the
identification of goitrous patients with a defect in the
accumulation of iodide in the thyroid tissue. Interestingly, the
first report in the literature describing a patient with an ITD
phenotype was reported as early as 1957 [11].
However, it was not until the isolation of the
complementary DNA encoding the transporter mediating the
active accumulation of iodide in the thyroid tissue—the
sodium iodide symporter (NIS)—that the cause of ITD was
elucidated for the first time at the molecular level.
Sodium Iodide Symporter (NIS)
Active iodide accumulation in the thyroid tissue is mediated
by NIS, an integral plasma membrane glycoprotein located on
the basolateral surface of the thyroid follicular cell [12]. NIS
represents a highly specialized transport system mediating the
accumulation of iodide from the bloodstream into the thyroid
follicular cell as well as a number of extra-thyroidal tissues,
including lactating breast, salivary glands, stomach, small
intestine, and choroid plexus [13-17].
The human slc5a5 gene, which encodes NIS, is located on
chromosome 19p12–13 with an open reading frame of 1,929
nucleotides encoding a 643-amino acid protein with a
molecular mass of approximately 50 kDa [18]. The coding
region of human NIS comprises 15 exons spanning 23.2 kb,
encoding for a 3.9 kb mRNA [18,19]. The current
experimentally tested NIS secondary structure model predicts
a protein with 13 transmembrane segments (TMSs), an
extracellular amino-terminus and a large intracellular carboxyl-
terminus (Figure 1) [20,21]. This model has been reinforced by
the determination of the crystal structure of the Vibrio
parahaemolyticus.
Na+/galactose transporter (vSGLT), a bacterial homologue of
the human SGLT1 [22]. Remarkably, NIS shares 27% identity
and 58% homology with vSGLT—almost as much as SGLT1
does (31% identity, 62% homology). Therefore, using the
crystal structure of vSGLT as a template, Paroder-Belenitsky et
al. [23] generated a 3D homology model of NIS. Significantly,
the NIS homology model has been extremely valuable in the
functional characterization of ITD-causing NIS mutants.
The protein sequence of human NIS presents three cores N-
glycosylation sites at N225, N489, and N502 located in the
third and sixth extracellular loops (Figure 1). All three sites are
N-glycosylated turning NIS into a highly glycosylated protein
[21]. The electrophoretic pattern of NIS comprises partially
glycosylated (60 kDa) and fully glycosylated (100 kDa)
polypeptides. Fully glycosylated NIS is the functional
polypeptide targeted to the plasma membrane. However, in
non-polarized cells, N-glycosylation is not critical for NIS
activity or its targeting to the plasma membrane [21,24].
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Figure 1: Iodide transport defect (ITD)–causing NIS mutations. Secondary structure model showing NIS protein mutations
identified in ITD patients. Black rectangles represent the 13 TMSs, which are numbered using Arabic numerals. Triangles
located in the third and sixth extracellular loops indicate N-glycosylation sites. Red circles indicate approximately where the
mutated residues are located. The region of the protein missing in the ITD mutant DelM142-Q323 NIS is shown in gray. Amino
acids are indicated with the single-letter code. Del: deletion; X: stop codon; fs: frame shift.
NIS transports one iodide ion against its electrochemical
gradient together with two sodium ions along their
electrochemical gradient maintained by the activity of Na+/K+-
ATPase [25]. Although the main known physiological role of
NIS function is to transport iodide, NIS has also been
demonstrated to transport other structurally similar anions
[25]. Significantly, NIS mediates the accumulation of 99mTc-
pertechnetate and, therefore, it is widely used for thyroid
scintigraphy [26]. However, unlike iodide, which is both
accumulated and covalently incorporated into thyroglobulin in
the thyroid, pertechnetate is only accumulated in the thyroid.
Another clinically relevant NIS substrate is the environmental
pollutant and well known inhibitor of thyroidal iodide uptake
perchlorate. The blockage of iodide transport by perchlorate
has been used in the treatment of hyperthyroidism, and is
currently used in the perchlorate discharge test to evaluate
iodide organification defects [27].
Studying the mechanism of NIS-mediated perchlorate
transport, Dohán et al. [28] uncovered that NIS translocates
different substrates with different stoichiometries, a property
that had not been reported in any other transporter. The
authors evaluated the kinetic parameters of NIS-mediated
perchlorate transport using the structurally related anion
186Re-perrhenate. The initial rates of perrhenate transport—as
a function of extracellular Na+—yielded a hyperbolic curve
indicative of an electroneutral stoichiometry (1 sodium/1
perrhenate or perchlorate), which stands in stark contrast to
the electrogenic (2 sodium/1 iodide) transport of iodide [28].
Iodide accumulation in the thyroid follicular cell is a
remarkable process given that the concentration of iodide in
the blood is in the sub-micromolar range—well below the
affinity of NIS for iodide—and the difficulty of binding halide
ions with high affinity. Using statistical thermodynamics,
Nicola et al. [29] reported that NIS overcomes this problem by
taking advantage of the extracellular concentration of sodium
and the increase in affinity for iodide that occurs when the
sodium binds to the transporter. Significantly, at the
physiological concentration of sodium, 79% of NIS molecules
are occupied by two sodium ions, and hence poised to bind
and transport iodide [29].
Genetic Causes of Iodide Transport
Defect (ITD)
Shortly after the cloning of NIS [12], the first loss-of-function
mutation in slc5a5 was described in a Japanese patient
diagnosed with congenital hypothyroidism due to a failure to
concentrate radioiodide in the saliva and a clinical response to
potassium iodide treatment [30]. Up to date, patients with ITD
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were found to be homozygous or compound heterozygous for
sixteen different loss-of-function mutations in the slc5a5 gene
(-54C>T, V59E, G93R, R124H, Q267E, V270E, C272X,
Y324LfsX12, T354P, G395R, S509RfsX6, Y531X, G543E,
DelM143-Q323, DelV287-G288, and DelA439-P443) (Figure 1).
They are either nonsense, alternative splicing, frame-shift,
deletion, or missense mutations of the slc5a5 gene.
Significantly, no mutation in other genes related to NIS
function or targeting to the plasma membrane have been
reported as cause of ITD.
As shown in Figure 1, most ITD-causing NIS mutants have
been reported within the open reading frame encoding the
transporter. In addition, a mutation in the 5’ untranslated
region of NIS, a C to T transition at nucleotide -54 (-54C>T) that
reduces NIS translation efficiency with a subsequent decrease
in the functional expression of the transporter, has been
reported [31].
The clinical evaluation of patients with different loss-of-
function slc5a5 mutations has demonstrated a substantial
clinical and biochemical heterogeneity. The onset of
hypothyroidism has varied from birth to childhood and seems
to correlate with the residual mutant NIS activity across slc5a5
defects [8]. Significantly, less than 10% of patients with
neonatal screening-detected ITD evidenced clinical signs of
hypothyroidism [8]. The presence of residual mutant NIS
activity, which is compatible with the presence of reduced,
although not absent, radioiodide uptake, revealed by thyroid
scintigraphy constitutes a possible explanation for the
difference in the age of onset on hypothyroidism. In this
context, the increase in TSH levels following a reduction in
thyroid hormone production may partially overcome the
defect in mutant NIS function by enhancing NIS expression, as
occurred in patients with ITDs carrying the missense mutation
T354P [32]. In agreement, a TSH-induced overstimulation of
the thyroid gland results in high serum thyroglobulin levels
[33]. In sharp contrast, patients harboring homozygous fully
inactive NIS mutants developed hypothyroidism with
significant clinical manifestations as a neonate [8]. Moreover, a
marked clinical heterogeneity has been reported in patients
harboring the same NIS mutant, especially concerning onset
and severity of hypothyroidism and the development of goiter.
Indeed, the clinical heterogeneity was first reported in a large
series of patients carrying the NIS mutant T354P [34]. The
amount of iodide intake significantly influences thyroid
function in patients with ITD, especially in those whose mutant
NIS protein retain residual activity. Breast milk contains much
larger amounts of iodide than artificial milk, particularly in
lactating mothers who take large amounts of seafood,
especially seaweed. Significantly, marked differences in
hypothyroidism onset were noticed between siblings feed with
breast milk or artificial milk during infancy [34].
Molecular Characterization of ITD-
Causing NIS Mutants
The detailed molecular study of ITD-causing NIS mutants has
provided key mechanistic information on NIS structure/
function; in particular, residues have been identified that are
critical for substrate binding, specificity, stoichiometry, and
plasma membrane targeting.
The molecular analysis of the NIS mutant T354P—the first
ITD-causing NIS mutant identified—revealed that NIS function
requires a hydroxyl group at the β-carbon at this position [35],
and led to the study of other β-hydroxyl group-containing
residues in TMS IX. De la Vieja et al. [36] demonstrated that
substitutions at position 354 and neighboring β-hydroxyl
group-containing residues modify the apparent affinity of the
protein for sodium, suggesting that these residues are involved
in sodium coordination and translocation. The authors
proposed the existence of a putative structural homology
between NIS and the Aquifex aeolicus leucine transporter
(LeuT)—the first sodium-driven transporter whose structure
was solved by X-ray crystallography, despite a lack of primary
sequence homology [36]. Consistent with this prediction, the
crystal structure of several sodium-coupled transporters,
including the Vibrio parahaemolyticus sodium/galactose
transporter (vSGLT), which belongs to the same family as NIS
[sodium/solute cotransporter family 5A (SLC5A5)] [22],
revealed that these transporters shared the same fold as LeuT.
Surprisingly, although the transporters share little sequence
homology, all share a similar mechanism for sodium
coordination, thus evidencing a structural convergent
evolutionary process for sodium-driven transporters.
Paroder-Belenitsky et al. [23] have uncovered unexpected
mechanistic information on NIS by the detailed molecular
characterization of the ITD-causing G93R NIS mutant. The lack
of activity of the G93R NIS mutant was found not to be due to
impaired trafficking to the plasma membrane or to the positive
charge conferred by Arg in the middle of TMS 3. Instead,
certain amino acid replacements at this position caused a
significant change in the apparent affinity for iodide. In
addition, position 93 showed to be critical for substrate
stoichiometry and specificity as G93N/T/Q/E NIS mediates
electrogenic transport of perrhenate and perchlorate, in
contrast to the electroneutral stoichiometry of wild-type NIS;
and although G93E and Q NIS discriminate between
substrates, as they do not transport iodide but they mediate
electrogenic transport of perrhenate and perchlorate.
Furthermore, based on the NIS 3D homology model, Paroder-
Belenitsky et al. [23] proposed that G93 acts as a pivot in going
from an outwardly to an inwardly open conformation during
the transport cycle.
The thorough characterization of the ITD-causing NIS
mutations R124H and DelA439-P443 has demonstrated the
importance of intramolecular interactions for proper NIS
folding [24,37]. Paroder et al. [37] reported that R124H NIS is
retained intracellularly in the endoplasmic reticulum and,
surprisingly, intrinsically active. As a result, R124H NIS is not
targeted to the plasma membrane and therefore does not
mediate any iodide transport in transfected cells. Significantly,
amino acid substitutions at position 124, located in
intracellular loop 2 (IL-2), revealed a key structural role for the
δ-amino group of R124, a highly conserved residue throughout
the SLC5A5 family, in NIS targeting to the plasma membrane.
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Indeed, an intramolecular interaction between the δ-amino
group of R124 and the thiol group of C440, located in IL-6, is
critical for the local folding required for NIS sorting out
through endoplasmic reticulum quality-control system [37]. Li
et al. demonstrated that DelA439-P443 NIS is also retained in
the endoplasmic reticulum but intrinsically inactive [24]. To
study the defect caused by the deleted residues, the authors
engineered five consecutive Ala residues at positions A439–
P443, which partially recovered plasma membrane targeting.
Strikingly, when only N441 was restored in the five Ala
background, the resulting NIS protein was fully targeted to the
plasma membrane [24]. Using the NIS 3D homology model,
the authors proposed that the side chain of N441—a residue
conserved throughout most of the SLC5A5 family members,
interacts with the main chain amino group of G444, capping
the helix of TMS 12 and thus stabilizing the structure of the
molecule.
Very recently, Nicola et al. [38] reported novel compound
heterozygous loss-of-function NIS mutations—R124H and
V270E—as cause of ITD in a Jamaican pediatric patient with a
peculiar phenotype: stunted growth but no cognitive
deficiency. According to the 3D NIS homology model, V270 is
placed at the intracellular end of TMS 7. The authors showed
that V270E markedly reduces iodide uptake when the protein
is heterologously expressed, because targeting of V270E NIS to
the plasma membrane is severely impaired. Strikingly,
membrane vesicles from V270E NIS-expressing cells
transported as much iodide as membrane vesicles from wild-
type NIS expressing cells, indicating that the mutant protein is
intrinsically active, thus a negative charge at position 270 does
not destabilize the protein but rather interferes its trafficking
to the plasma membrane [38]. The negative charge imparted
by Glu at position 270 induced a subtle change in the surface
charge of a positive patch in the intracellularly facing domain
of the mutant NIS molecule that may hinder the interaction
with proteins critical for its trafficking to the cell surface [38].
In conclusion, a nonpolar residue at position 270, which all
members of the SLC5A5 family have, is required for proper NIS
maturation and plasma membrane trafficking.
Concluding Remarks
Genetic screening should be considered in all pediatric
patients with permanent hypothyroidism in conjunction with
low or absent radioiodide uptake even in the absence of goiter.
In case that thyroid scintigraphy data is not available, patients
with goitrous hypothyroidism associated with high serum
thyroglobulin levels should be first evaluated for organification
defects. In addition to providing a definitive diagnosis, the
identification of mutations in slc5a5 may have further clinical
implications. Genetic diagnosis of a proband will allow
subsequent preclinical diagnoses of younger siblings in the
same family as patients with delayed onset on clinical
hypothyroidism in ITD had already signs of developmental
delay at time of diagnosis [38]. Moreover, concerning
treatment options, iodide supplementation can improve
thyroid function in patients with residual NIS activity and
should be considered, either as adjunct or alternative
treatment to levothyroxine replacement.
In addition to the fundamental role of NIS for thyroid
hormone synthesis, NIS-mediated iodide accumulation in the
thyroid gland constitutes the molecular basis for the diagnosis
and treatment of thyroid cancer based on radioiodide therapy
[39]. For over 70 years, radioiodide therapy has been the
mainstay therapy for radioiodide-avid locally advanced and
metastatic thyroid carcinomas. Retrospective studies have
demonstrated that the ability of tumor cells to accumulate
radioiodide is the best indicator of disease-free survival [40].
However, differentiated thyroid tumors often exhibit reduced
(or even undetectable) iodide transport compared to normal
thyroid tissue. Immunohistochemical analysis revealed that
70-80% of thyroid tumors overexpress NIS compared to
adjacent normal tissue. Surprisingly, NIS expression was mainly
located in intracellular compartments suggesting the presence
of cell surface trafficking abnormalities. The mechanisms
leading to reduced NIS trafficking to the plasma membrane in
thyroid tumors constitutes still a major open question in the
thyroid field. Significantly, considering the substantial
information regarding NIS structure/function obtained through
the study of naturally occurring NIS mutants, the identification
and further molecular characterization of novel ITD-causing
NIS mutants supposes a promise strategy to uncover the
mechanisms mediating NIS targeting to the plasma membrane
in thyroid follicular cells.
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